# Immunic, Inc.: financial statements, quarterly

IMUX · Nasdaq · CIK 1280776 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imux.md) · [Financials](/companies/imux/financials.md) · [Filings](/companies/imux/filings.md) · [Insiders](/companies/imux/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/imux/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [19.8](/filings/0001280776-24-000018.md) | [19.3 d](/filings/0001280776-25-000005.md) | [18.7](/filings/0001280776-25-000008.md) | [18.3](/filings/0001280776-25-000012.md) | [21.4](/filings/0001280776-25-000017.md) | [21.6 d](/filings/0001280776-26-000005.md) | [21.5](/filings/0001280776-26-000010.md) | [21.4](/filings/0001280776-26-000018.md) | [20.0](/filings/0001280776-25-000017.md) | [19.1 d](/filings/0001280776-26-000005.md) | [25.6](/filings/0001280776-26-000010.md) | [25.9](/filings/0001280776-26-000018.md) |
| Operating income | $m | [(23.6)](/filings/0001280776-24-000018.md) | [(23.4) d](/filings/0001280776-25-000005.md) | [(23.9)](/filings/0001280776-25-000008.md) | [(22.8)](/filings/0001280776-25-000012.md) | [(25.7)](/filings/0001280776-25-000017.md) | [(25.6) d](/filings/0001280776-26-000005.md) | [(26.8)](/filings/0001280776-26-000010.md) | [(27.1)](/filings/0001280776-26-000018.md) | [(26.0)](/filings/0001280776-25-000017.md) | [(23.3) d](/filings/0001280776-26-000005.md) | [(33.2)](/filings/0001280776-26-000010.md) | [(35.3)](/filings/0001280776-26-000018.md) |
| Net income | $m | [(22.8)](/filings/0001280776-24-000018.md) | [(21.6) d](/filings/0001280776-25-000005.md) | [(29.6)](/filings/0001280776-25-000017.md) | [(21.4)](/filings/0001280776-25-000017.md) | [(24.4)](/filings/0001280776-25-000017.md) | [(25.2) d](/filings/0001280776-26-000005.md) | [(25.5)](/filings/0001280776-26-000018.md) | [(26.8)](/filings/0001280776-26-000018.md) | [(25.6)](/filings/0001280776-25-000017.md) | [(19.3) d](/filings/0001280776-26-000005.md) | [(32.6)](/filings/0001280776-26-000018.md) | [(34.1)](/filings/0001280776-26-000018.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0001280776-24-000018.md) | not reported | [(0.30)](/filings/0001280776-25-000008.md) | [(0.21)](/filings/0001280776-25-000012.md) | [(0.24)](/filings/0001280776-25-000017.md) | not reported | [(2.51)](/filings/0001280776-26-000010.md) | [(2.03)](/filings/0001280776-26-000018.md) | [(0.13)](/filings/0001280776-25-000017.md) | not reported | [(1.08)](/filings/0001280776-26-000010.md) | [(0.80)](/filings/0001280776-26-000018.md) |
| Basic EPS | $ per share | [(0.51)](/filings/0001280776-24-000018.md) | not reported | [(0.30)](/filings/0001280776-25-000008.md) | [(0.21)](/filings/0001280776-25-000012.md) | [(0.24)](/filings/0001280776-25-000017.md) | not reported | [(2.51)](/filings/0001280776-26-000010.md) | [(2.03)](/filings/0001280776-26-000018.md) | [(0.13)](/filings/0001280776-25-000017.md) | not reported | [(1.08)](/filings/0001280776-26-000010.md) | [(0.80)](/filings/0001280776-26-000018.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [59.7](/filings/0001280776-23-000018.md) | [46.7](/filings/0001280776-25-000005.md) | [97.3](/filings/0001280776-24-000009.md) | [79.7](/filings/0001280776-24-000014.md) | [59.1](/filings/0001280776-24-000018.md) | [35.7](/filings/0001280776-26-000005.md) | [14.3](/filings/0001280776-25-000008.md) | [55.3](/filings/0001280776-25-000012.md) | [35.1](/filings/0001280776-25-000017.md) | [15.5](/filings/0001280776-26-000018.md) | [187](/filings/0001280776-26-000010.md) | [155](/filings/0001280776-26-000018.md) |
| Current assets | $m | [65.2](/filings/0001280776-23-000018.md) | [52.5](/filings/0001280776-25-000005.md) | [103](/filings/0001280776-24-000009.md) | [85.0](/filings/0001280776-24-000014.md) | [63.3](/filings/0001280776-24-000018.md) | [39.3](/filings/0001280776-26-000005.md) | [19.0](/filings/0001280776-25-000008.md) | [59.8](/filings/0001280776-25-000012.md) | [39.3](/filings/0001280776-25-000017.md) | [22.9](/filings/0001280776-26-000018.md) | [189](/filings/0001280776-26-000010.md) | [158](/filings/0001280776-26-000018.md) |
| Total assets | $m | [67.0](/filings/0001280776-23-000018.md) | [54.3](/filings/0001280776-25-000005.md) | [104](/filings/0001280776-24-000009.md) | [86.5](/filings/0001280776-24-000014.md) | [64.8](/filings/0001280776-24-000018.md) | [40.9](/filings/0001280776-26-000005.md) | [20.5](/filings/0001280776-25-000008.md) | [61.4](/filings/0001280776-25-000012.md) | [40.7](/filings/0001280776-25-000017.md) | [24.1](/filings/0001280776-26-000018.md) | [190](/filings/0001280776-26-000010.md) | [159](/filings/0001280776-26-000018.md) |
| Current liabilities | $m | [17.8](/filings/0001280776-23-000018.md) | [24.7](/filings/0001280776-25-000005.md) | [20.1](/filings/0001280776-24-000009.md) | [22.7](/filings/0001280776-24-000014.md) | [23.4](/filings/0001280776-24-000018.md) | [22.2](/filings/0001280776-26-000005.md) | [25.6](/filings/0001280776-25-000008.md) | [27.3](/filings/0001280776-25-000012.md) | [30.1](/filings/0001280776-25-000017.md) | [30.6](/filings/0001280776-26-000018.md) | [38.4](/filings/0001280776-26-000010.md) | [31.3](/filings/0001280776-26-000018.md) |
| Total liabilities | $m | [18.6](/filings/0001280776-23-000018.md) | [25.4](/filings/0001280776-25-000005.md) | [20.6](/filings/0001280776-24-000009.md) | [22.9](/filings/0001280776-24-000014.md) | [23.5](/filings/0001280776-24-000018.md) | [22.4](/filings/0001280776-26-000005.md) | [25.8](/filings/0001280776-25-000008.md) | [27.5](/filings/0001280776-25-000012.md) | [30.2](/filings/0001280776-25-000017.md) | [30.7](/filings/0001280776-26-000018.md) | [38.5](/filings/0001280776-26-000010.md) | [31.6](/filings/0001280776-26-000018.md) |
| Shareholders' equity | $m | [48.4](/filings/0001280776-24-000018.md) | [28.9](/filings/0001280776-26-000005.md) | [83.6](/filings/0001280776-25-000017.md) | [63.6](/filings/0001280776-25-000017.md) | [41.2](/filings/0001280776-25-000017.md) | [18.4](/filings/0001280776-26-000018.md) | [(5.3)](/filings/0001280776-26-000018.md) | [33.9](/filings/0001280776-26-000018.md) | [10.5](/filings/0001280776-25-000017.md) | [(6.7)](/filings/0001280776-26-000018.md) | [151](/filings/0001280776-26-000018.md) | [128](/filings/0001280776-26-000018.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.3) d](/filings/0001280776-24-000018.md) | [(14.0) d](/filings/0001280776-25-000005.md) | [(24.0)](/filings/0001280776-25-000008.md) | [(17.0) d](/filings/0001280776-25-000012.md) | [(20.8) d](/filings/0001280776-25-000017.md) | [(23.0) d](/filings/0001280776-26-000005.md) | [(21.8)](/filings/0001280776-26-000010.md) | [(24.6) d](/filings/0001280776-26-000018.md) | [(20.1) d](/filings/0001280776-25-000017.md) | [(19.3) d](/filings/0001280776-26-000005.md) | [(17.3)](/filings/0001280776-26-000010.md) | [(31.0) d](/filings/0001280776-26-000018.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001280776-24-000018.md) | [0.2 d](/filings/0001280776-25-000005.md) | [0.0](/filings/0001280776-25-000008.md) | [0.2 d](/filings/0001280776-25-000012.md) | [0.1 d](/filings/0001280776-25-000017.md) | [0.0 d](/filings/0001280776-26-000005.md) | [0.0](/filings/0001280776-26-000010.md) | [0.0 d](/filings/0001280776-26-000018.md) | [0.1 d](/filings/0001280776-25-000017.md) | [0.0 d](/filings/0001280776-26-000005.md) | [0.0](/filings/0001280776-26-000010.md) | [0.2 d](/filings/0001280776-26-000018.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.6](/filings/0001280776-23-000018.md) | [43.7](/filings/0001280776-24-000009.md) | [44.4](/filings/0001280776-24-000014.md) | [44.6](/filings/0001280776-24-000018.md) | [97.3](/filings/0001280776-25-000008.md) | [101](/filings/0001280776-25-000012.md) | [101](/filings/0001280776-25-000017.md) | [10.1](/filings/0001280776-26-000010.md) | [13.2](/filings/0001280776-26-000018.md) | [194](/filings/0001280776-25-000017.md) | [30.1](/filings/0001280776-26-000010.md) | [42.5](/filings/0001280776-26-000018.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,644,467 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0001280776-26-000018.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.